Cyclo therapeutics announces closing of $5.0 million private placement with rafael holdings, inc.

Gainesville, fla.--(business wire)--cyclo therapeutics, inc. (nasdaq: cyth) (“cyclo therapeutics” or the “company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed the previously announced private placement with rafael holdings, inc. (nyse:rfl) (“rafael”) for the purchase of 4,000,000 shares of common stock of cyclo therapeutics and warrants t.
RFL Ratings Summary
RFL Quant Ranking